Noxopharm Ltd. · ASX:NOX
Noxopharm — FNN – Shaw&Partners Investor Event (August 2018)
22 slides from Noxopharm's conference presentation, Aug 14, 2018
Slide 1: Noxopharm Corporate Presentation
For personal use only Date: 14 August, 2018 Sydney, Australia ASX: NOX NOXOPHARM CORPORATE PRESENTATION Noxopharm Limited FNN – SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Sydney, 14 August 2018: Noxopharm (ASX:NOX) is pleased to Suite 3, Level 4 provide
Slide 2: Forward Looking Statements
“continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about c
Slide 3: Discover Develop Deliver
For personal use only Discover ASX: NOX Develop Deliver 1
Slide 4: Corporate objective
Corporate objective For personal use only To bring to market in 2022 the first approved radio-enhancer that boosts the the effect of radiotherapy ❖ Potently NOX66 ❖ Safely ❖ Cost-effectively 2
Slide 5: Radio-enhancement
Radio-enhancement For personal use only ➢ Radiation ‘burns’ DNA strands AIM = ➢ Cell attempts to repair ➢ Block repair of damage DNA damage ➢ If repair successful, cell survives (but at risk of further ➢ Applied dose of cancer) radiotherapy kills ➢ If repair unsuccessful, cell dies more cancer cells
Slide 6: Radio-enhancement: NOX66
Radio-enhancement NOX66 For personal use only Previous attempts to develop a ❑ First-in-class dual-action radio- radio-enhancing drug: enhancer: ➢ Aimed at blocking DNA repair 1. Blocks cell division – DNA more ➢ (PARP-1 inhibitors) susceptible to radiation ➢ No repair = cell dies 2. Blocks repair o
Slide 7: Initial clinical use of NOX66: Compassionate case #1
Initial clinical use of NOX66 For personal use only Compassionate case #1 • Late-stage prostate cancer • Tumours in spine, lymph nodes, bone • NOX66 + palliative radiotherapy to spinal and LN tumours • 10-week scan = complete response in irradiated tumours • Complete response in all other (non-irrad
Slide 8: Initial clinical use of NOX66: Compassionate case #2
Initial clinical use of NOX66 For personal use only Compassionate case #2 Prior to NOX66 + • Leiomyosarcoma radiotherapy • Primary in abdomen • Secondaries in lungs • NOX66 + palliative radiotherapy to primary lesion only • Partial shrinkage of lung secondary tumours • Patient remains well and 3 mon
Slide 9: 'Abscopal Effect'
‘Abscopal Effect’ For personal use only ➢ Irradiation of a selected tumour leads to response in distant tumours ➢ Extremely rare phenomenon ➢ Introduction of immuno- ➢ Radiation kills cancer cells oncology drugs (PD-1/PD-L1 ➢ Cancer (non-self) antigens drugs) and GM-CSF has released increased occurr
Slide 10: Radio-enhancement: Direct and Abscopal
Radio-enhancement: DIRECT and ABSCOPAL For personal use only + NOX66 Direct response Partial abscopal response Complete abscopal response 8
Slide 11: Abscopal-inducing drugs
Abscopal-inducing drugs Radiotherapy only Enhanced response in + abscopal response irradiated tumours For personal use only Assume a patient with multiple tumours: 2 tumours are irradiated ++ +++ +++ +++ Symptoms (pain) +++ ++ ++ +++ +++ Clinical benefit Quality of Life ++ Time to disease ++ ++ ++++
Slide 12: NOX66: Immuno-oncology drug
NOX66: Immuno-oncology drug For personal use only Confirmed: NOX66 increases activity of natural killer (NK) cells. NK cells are the body’s first line of defence against cancer cells 10
Slide 13: Radio-enhancement capability comparison
Radio-enhancement capability comparison For personal use only NOX66 PD-1/PD-L1 drugs YES NO Direct radio-enhancement YES Monotherapy effect limited to certain tumor types Wide cancer spectrum Target on all cancer cells No dose-limiting Dose-limiting toxicities (eg Well tolerated toxicities known bow
Slide 14: DARRT-1 Clinical Study
DARRT-1 Clinical Study ➢ Late-stage prostate cancer For personal use only • Metastatic castrate-resistant disease • no remaining treatment options Cohort 1: 4 patients. 400 mg NOX66 ➢ Eligible for palliative radiotherapy for symptom relief Cohort 2: 4 patients. 800 mg NOX66 ➢ Radiotherapy for 5 days
Slide 15: DARRT-1 Clinical Study: interim data
DARRT-1 Clinical Study: interim data For personal use only 6-weeks 12-weeks 400 mg Cohort 1: 400 mg NOX66 3x stable disease Cohort 2: 800 mg NOX66 1x partial abscopal Cohort 3: 1200 mg NOX66 1x partial abscopal 13
Slide 16: DARRT-1: Anticipated data read-out timetable
DARRT-1: Anticipated data read-out timetable For personal use only Cohorts 1, 2 and 3 12 weeks assessment Q4 2018 Q1 2019 Q2 2019 Cohort 4 12 weeks assessment Cohorts 1, 2 and 3 24 weeks assessment 14
Slide 17: DARRT Program Strategy 2019
DARRT Program Strategy 2019 Brain cancer (GBM) For personal use only (Aust) Lung cancer (China) Multinational study (up to 50 sites) Phase 3 Pivotal Planning has commenced: study • CRO appointed Prostate cancer DARRT • Advisory Board met 20-30 Gy Head & 10-14 days NOX66 neck cancer (SE Asia) Project
Slide 18: What I haven't mentioned
What I haven’t mentioned …….. For personal use only Lu-PSMA program in late-stage prostate cancer. Phase 1b 16-man study. (Fully recruited) CEP (chemo-sensitising) program 2nd generation IDRONOXIL dosage formulation studies 16
Slide 19: Key metrics
Key metrics For personal use only Shares outstanding 122M : 91M free + 31M escrowed (May 2019) Other 22.5M options ($0.30) (2021) Market Cap $73M CEO Directors Other founders8 IPO price (Aug 2016) 20 cents Others Last traded 60 cents Cash position AU$ 11.9M (30 June 2018) 17
Slide 20: Key Investment Messages
Key Investment Messages For personal use only AUSTRALIAN SCIENCE MANAGEMENT EXPERIENCED IN DRUG DEVELOPMENT AND PUBLIC COMPANIES TRACK RECORD OF INVESTOR RELATIONS AND CAPITAL RAISINGS SUFFICIENTLY FUNDED TO RUN CURRENT PHASE 1/2 PROGRAMS A SUCCESSFUL OUTCOME IS A SHARE OF THE $100 BILLION ONCOLOGY
Slide 21: Disclaimer
Disclaimer For personal use only • This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to purchase any shares in NOX. No agreement to subscribe for secu
Slide 22: Dr Graham Kelly, Chief Executive Officer
For personal use only Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 20
Noxopharm — FNN – Shaw&Partners Investor Event (August 2018) on 6ix